Cargando…
Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
BACKGROUND: Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging. CASE PRESENTATION: A 67-yea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593802/ https://www.ncbi.nlm.nih.gov/pubmed/28895097 http://dx.doi.org/10.1186/s40792-017-0378-z |
_version_ | 1783263096504057856 |
---|---|
author | Nakatake, Richi Ishizaki, Morihiko Matui, Kosuke Yanagimoto, Hiroaki Inoue, Kentaro Kaibori, Masaki Kawaguchi, Yusai Kon, Masanori |
author_facet | Nakatake, Richi Ishizaki, Morihiko Matui, Kosuke Yanagimoto, Hiroaki Inoue, Kentaro Kaibori, Masaki Kawaguchi, Yusai Kon, Masanori |
author_sort | Nakatake, Richi |
collection | PubMed |
description | BACKGROUND: Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging. CASE PRESENTATION: A 67-year-old man was admitted to our department because of a liver tumor. Computed tomography revealed a single liver tumor 50 mm in diameter and located in the S3 region. Biopsy and imaging findings resulted in a diagnosis of primary hepatic neuroendocrine carcinoma. Left lateral segmentectomy was performed. Immunohistochemically, the tumor cells were positive for synaptophysin, chromogranin A, and CD56. Ki-67 was positive in > 90% of the tumor cells. The final diagnosis was primary hepatic neuroendocrine carcinoma. The patient suffered two episodes of lymph node recurrence. Nonetheless, the tumor was excised to prolong survival. Thus, after lymphadenectomy, he received adjuvant chemotherapy for 6 months. Two years after surgery, the patient remains alive and in good general condition. CONCLUSIONS: In most cases, primary hepatic neuroendocrine carcinoma, while extremely rare, has a poor prognosis. At present, surgical resection is a priority for curative treatment, but in patients with recurrence, combined therapies are recommended. |
format | Online Article Text |
id | pubmed-5593802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-55938022017-09-27 Combination therapies for primary hepatic neuroendocrine carcinoma: a case report Nakatake, Richi Ishizaki, Morihiko Matui, Kosuke Yanagimoto, Hiroaki Inoue, Kentaro Kaibori, Masaki Kawaguchi, Yusai Kon, Masanori Surg Case Rep Case Report BACKGROUND: Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging. CASE PRESENTATION: A 67-year-old man was admitted to our department because of a liver tumor. Computed tomography revealed a single liver tumor 50 mm in diameter and located in the S3 region. Biopsy and imaging findings resulted in a diagnosis of primary hepatic neuroendocrine carcinoma. Left lateral segmentectomy was performed. Immunohistochemically, the tumor cells were positive for synaptophysin, chromogranin A, and CD56. Ki-67 was positive in > 90% of the tumor cells. The final diagnosis was primary hepatic neuroendocrine carcinoma. The patient suffered two episodes of lymph node recurrence. Nonetheless, the tumor was excised to prolong survival. Thus, after lymphadenectomy, he received adjuvant chemotherapy for 6 months. Two years after surgery, the patient remains alive and in good general condition. CONCLUSIONS: In most cases, primary hepatic neuroendocrine carcinoma, while extremely rare, has a poor prognosis. At present, surgical resection is a priority for curative treatment, but in patients with recurrence, combined therapies are recommended. Springer Berlin Heidelberg 2017-09-11 /pmc/articles/PMC5593802/ /pubmed/28895097 http://dx.doi.org/10.1186/s40792-017-0378-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Case Report Nakatake, Richi Ishizaki, Morihiko Matui, Kosuke Yanagimoto, Hiroaki Inoue, Kentaro Kaibori, Masaki Kawaguchi, Yusai Kon, Masanori Combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
title | Combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
title_full | Combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
title_fullStr | Combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
title_full_unstemmed | Combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
title_short | Combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
title_sort | combination therapies for primary hepatic neuroendocrine carcinoma: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593802/ https://www.ncbi.nlm.nih.gov/pubmed/28895097 http://dx.doi.org/10.1186/s40792-017-0378-z |
work_keys_str_mv | AT nakatakerichi combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT ishizakimorihiko combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT matuikosuke combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT yanagimotohiroaki combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT inouekentaro combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT kaiborimasaki combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT kawaguchiyusai combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport AT konmasanori combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport |